Stockscreener 앱 받기
70.93
0.15%
-0.11
시간 외 거래:
70.93
Disc Medicine Inc 주식(IRON)의 최신 뉴스
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers - MSN
Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8% - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA Action - Benzinga
Disc Medicine (IRON) Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance - Yahoo Finance
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
Klein Hersh Recruits CHRO for Disc Medicine - Hunt Scanlon Media
Disc Medicine (IRON) Stock Declines Amid Market Movement - GuruFocus
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run - AOL.com
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - Reuters
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - TradingView — Track All Markets
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Asianet Newsable
Disc Medicine stock rating reiterated by Morgan Stanley amid FDA review - Investing.com Canada
Stifel remains bullish on Disc Medicine stock despite potential FDA delay - Investing.com Canada
Morgan Stanley Reaffirms Positive Outlook on IRON Despite FDA Re - GuruFocus
Disc Medicine (NASDAQ:IRON) Shares Gap DownShould You Sell? - MarketBeat
Experimental drug suspended❓💊 Shares od Disc Medicine lose as much as 7% 🚨 - XTB.com
Disc Medicine (IRON) Shares Decline as FDA Review Faces Brief De - GuruFocus
Disc Medicine (IRON) Faces Review Delay for Rare Disease Drug - GuruFocus
Fda pushes back review of Sanofi's diabetes drug Tzield and Disc Medicine's blood disorder drug -documents - marketscreener.com
How Disc Medicine’s New HR Chief and Bitopertin Review Could Shape IRON’s Commercial Readiness - Sahm
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Gainers: Should I hold or sell Disc Medicine Inc stock in 2025July 2025 WrapUp & Stepwise Entry/Exit Trade Alerts - Bộ Nội Vụ
Is Disc Medicine (IRON) Offering An Opportunity After Recent Volatility And DCF Valuation Gap - Yahoo Finance
Disc Medicine appoints Lisa Amaya Price as chief human resources officer - Investing.com Nigeria
Disc Medicine outlines 2026 pipeline priorities after NDA submission By Investing.com - Investing.com Nigeria
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer - citybiz
Disc Medicine (IRON) Appoints New Chief Human Resources Officer - GuruFocus
Disc Medicine appoints Lisa Amaya Price as chief human resources officer By Investing.com - Investing.com India
News | decaturdailydemocrat.comDisc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer - FinancialContent
Disc Medicine (IRON) Shares Strategic Goals and Pipeline Developments for 2026 - GuruFocus
Disc Medicine outlines 2026 pipeline priorities after NDA submission - Investing.com
Disc Medicine prepares for potential 2026 bitopertin FDA decision - TipRanks
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 - The Manila Times
FDA weighs new blood disorder drug as small biotech sets a pivotal 2026 - Stock Titan
The Technical Signals Behind (IRON) That Institutions Follow - Stock Traders Daily
Disc Medicine advances bitopertin in FDA pilot program - MSN
Aug Intraday: How supply chain issues affect Disc Medicine Inc. stockPrice Action & Daily Profit Focused Stock Screening - Улправда
Will Disc Medicine Inc. stock deliver strong dividend growthWeekly Trend Recap & Detailed Earnings Play Strategies - Улправда
A Look At Disc Medicine (IRON) Valuation After Bitopertin NDA Filing And Positive DISC-0974 Phase 2 Data - Sahm
How institutional buying supports Disc Medicine Inc. stockJuly 2025 Technicals & Technical Entry and Exit Tips - Улправда
How supply chain issues affect Disc Medicine Inc. stockWeekly Trading Summary & Intraday High Probability Setup Alerts - Улправда
Aug Selloffs: Why Disc Medicine Inc. stock is favored by top institutionsJuly 2025 Opening Moves & Growth Oriented Trade Recommendations - Улправда
All You Need to Know About Disc Medicine, Inc. (IRON) Rating Upgrade to Buy - MSN
Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Biotech targeting serious blood diseases to speak at J.P. Morgan - Stock Titan
Why Disc Medicine Inc. stock is seen as undervalued2026 world cup usa national team round of 16 young talents transition play winner prediction tactical review - Улправда
Disc Medicine, Inc. (IRON) Stock Analysis: Strong Buy Ratings and a Promising 54.73% Potential Upside - DirectorsTalk Interviews
Disc Medicine’s Cash Runway And NDA Milestones Could Be A Game Changer For IRON - Sahm
Disc Medicine (NASDAQ:IRON) Insider Sells $511,485.00 in Stock - MarketBeat
Disc Medicine Officer Sells Shares Under Trading Plan - TradingView — Track All Markets
Aug Catalysts: Will Disc Medicine Inc stock deliver strong dividend growth2025 Retail Activity & Safe Entry Momentum Tips - Bộ Nội Vụ
Disc Medicine: RALLY-MF Data Validates Pipeline Optionality (NASDAQ:IRON) - Seeking Alpha
Disc Medicine Earnings Notes - Trefis
Disc Medicine (IRON) stock today: year-end rally keeps January FDA decision in focus - TechStock²
Precision Trading with Disc Medicine Inc. (IRON) Risk Zones - Stock Traders Daily
Disc Medicine, Inc. (IRON) Stock Analysis: Poised for 55% Upside Potential Amid Robust Analyst Confidence - DirectorsTalk Interviews
Disc Medicine falls -14.3% - MSN
Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Disc Medicine (IRON) and Sagimet Biosciences, Inc. Class A (SGMT) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Moderna (MRNA) and Disc Medicine (IRON) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Disc Medicine (IRON) and BioMarin Pharmaceutical (BMRN) - The Globe and Mail
Disc Shares Slip Amid Report FDA’s Prasad is Skeptical of Bitopertin’s Efficacy - BioSpace
4.73%
0.92%
자본화:
|
볼륨(24시간):